Pantoprazolo Almus (Pantoprazole Sodium Sesquihydrate)

Pantoprazole, the active ingredient in Pantoprazolo Almus, is a proton pump inhibitor presented as a strength‑unknown oral dosage form for oral use. It reduces gastric acid production and is used to treat conditions such as gastro‑oesophageal reflux disease and related acid‑related disorders in adults.

GNH USA supplies Pantoprazolo Almus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Pantoprazolo Almus is a proton pump inhibitor that acts on the gastric acid secretion pathway to manage several acid‑related disorders.

- Gastro‑oesophageal reflux disease (GERD): helps heal erosive esophagitis and relieve heartburn symptoms. - Erosive esophagitis: promotes healing of the damaged esophageal lining. - NSAID‑induced gastric ulcer: reduces acid exposure to support ulcer healing. - Zollinger‑Ellison syndrome: controls excessive gastric acid production associated with the condition.

Pantoprazolo Almus may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: usually self‑limiting. - Nausea: occasional and transient. - Abdominal pain: mild discomfort. - Flatulence: excess gas. - Constipation: infrequent.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis risk. - Acute interstitial nephritis: kidney inflammation. - Severe hypersensitivity: rash, angioedema, anaphylaxis. - Low magnesium levels: may cause muscle cramps or arrhythmias. - Fracture risk: long‑term use linked to reduced bone density. - Liver enzyme elevation: potential hepatic impact.

Before starting Pantoprazolo Almus, consider the following safety points:

- Assess renal function: dose adjustment may be needed in severe impairment. - Review liver status: use with caution in hepatic disease. - Monitor electrolytes: prolonged therapy can affect magnesium and potassium. - Evaluate infection risk: PPIs may increase susceptibility to gastrointestinal infections. - Consider bone health: long‑term use may affect calcium balance. - Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Pantoprazolo Almus can affect the plasma concentrations of several co‑administered medicines.

Major Interactions (Avoid): - Ketoconazole oral suspension: reduced absorption due to higher gastric pH. - Atazanavir: markedly decreased plasma levels, risking treatment failure. - Clopidogrel: diminished antiplatelet effect, potentially increasing cardiovascular risk.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR, requiring closer monitoring. - Methotrexate: reduced renal clearance may raise toxicity risk. - Digoxin: slight increase in serum concentrations. - Mycophenolate mofetil: decreased exposure, may require dose adjustment.